Clik here to view.
Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan for Three New First-Line...
KENILWORTH, N.J. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck’s anti-PD-1 therapy, received new approvals from the Japan Pharmaceuticals...
View ArticleClik here to view.
ENHERTU® Approved in the U.S. for HER2 Positive Unresectable or Metastatic...
TOKYO & MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved...
View ArticleClik here to view.
2019年、5736人の世界で最も貧しい人々がテジ・コーリ角膜インスティテュートで視力を回復
ロンドン （ビジネスワイヤ） — ハイデラバードのテジ・コーリ角膜インスティテュートが創立4周年を迎え、テジ・コーリ財団は2020年より新たに1400万ドルの資金を提供します。2019年、5736人がテジ・コーリ角膜インスティテュートで失明や重度の視覚障害を治療しました。これは、ロンドンのテジ・コーリ財団と、世界保健機関協力センターであるハイデラバードのLVプラサド眼科研究所との共同活動です。...
View ArticleClik here to view.
心不全発症率の増加を抑制するための大規模なランダム化対照試験
ボストン （ビジネスワイヤ） — 心臓発作患者さんの治療方法を変えることで心不全発症率を低減させる有望な新療法を追究するピボタル多施設臨床試験が、現在進行中です。ST上昇型心筋梗塞（STEMI) ドア・ツー・アンローディング（DTU）ピボタルランダム化対照試験（STEMI...
View ArticleClik here to view.
Invicro LLC Announces Dr. Matthew Silva as New Chief Executive Officer and...
BOSTON Invicro LLC, a Konica Minolta company, today announces, Dr. Matthew Silva has been appointed as the new Chief Executive Officer. Dr. Silva will assume the day-to-day leadership...
View ArticleClik here to view.
インヴィクロがマシュー・シルビア博士の新最高経営責任者への任命とジャック・ホッピン博士のコニカミノルタプレシジョンメディシン社長への任命を発表
ボストン （ビジネスワイヤ） —...
View ArticleClik here to view.
Invicro LLC宣布Matthew Silva博士为新任首席执行官，Jack Hoppin博士被任命为Konica Minolta...
波士顿 (美国商业资讯)–柯尼卡美能达(Konica Minolta)旗下公司Invicro LLC今天宣布，Matthew Silva博士已被任命为公司新任首席执行官。Silva博士将负责公司的日常领导工作，并将加入Invicro董事会，即刻生效。Invicro联合创始人Jack Hoppin博士将不再担任Invicro首席执行官，转而出任Konica Minolta Precision...
View ArticleClik here to view.
Starpharma: Commencement of Phase 1 Trial for AZD0466 Utilising DEP® Delivery...
MELBOURNE, Australia Starpharma (ASX:SPL, OTCQX:SPHRY) today announced that AstraZeneca (LSE/STO/NYSE:AZN) has commenced a phase 1 clinical trial of AZD0466 (DEP® Bcl2/xL conjugate) and the first...
View ArticleClik here to view.
Dr. Reddy’s Laboratories Announces the Launch of Sodium Nitroprusside...
HYDERABAD, India & PRINCETON, N.J. Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the...
View ArticleClik here to view.
Turnstone Biologics Announces Global Collaboration and License Agreement with...
NEW YORK Turnstone Biologics, a biotechnology company pioneering the development of engineered viral immunotherapies, today announced a strategic collaboration with Takeda Pharmaceutical Company...
View ArticleClik here to view.
Psomagen-Macrogen Consortium Acquires All Patents and Data From US Company...
ROCKVILLE, Md. On January 2nd, the Psomagen-Macrogen Consortium announced the acquisition of all key assets of US company uBiome. Through the move, Psomagen has become a key player in the microbiome...
View ArticleClik here to view.
ENHERTU® Now Available in U.S. for HER2 Positive Unresectable or Metastatic...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that ENHERTU® (fam-trastuzumab deruxtecan-nxki), a HER2 directed antibody drug conjugate,...
View ArticleClik here to view.
Shanghai Foundation for Rare Disease Appoints CANbridge CEO, James Xue,...
BEIJING CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, announced that James...
View ArticleClik here to view.
GlycoMimetics and Apollomics Announce Exclusive Collaboration and License...
ROCKVILLE, Md. & FOSTER CITY, Calif. & HANGZHOU, China GlycoMimetics, Inc. (NASDAQ: GLYC), a leader in the field of applied glycotechnology for cancer, and Apollomics, Inc., an innovative...
View ArticleClik here to view.
MaveriX Oncology to Present at China Showcase 2020 and Biotech Showcase™ 2020...
PALO ALTO, Calif. MaveriX Oncology, Inc., a development-stage biotechnology company with a proprietary pipeline of targeted small-molecule chemo-immuno-therapeutics for the treatment of a broad...
View ArticleClik here to view.
Transgene and NEC Start Two Clinical Trials with TG4050, an AI-Powered Cancer...
STRASBOURG, France & TOKYO Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TOKYO:...
View ArticleClik here to view.
Transgene and NEC Start Two Clinical Trials with TG4050, an Individualized...
STRASBOURG, France & TOKYO Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and...
View ArticleClik here to view.
SAB Biotherapeutics Announces Research Collaboration With CSL Behring
SIOUX FALLS, S.D. SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company advancing a new class of immunotherapies, today announced that it has entered into multiple...
View ArticleClik here to view.
Transgene和NEC启动两项AI驱动型抗癌疫苗TG4050治疗卵巢癌和头颈部癌的临床试验
法国斯特拉斯堡和东京 (美国商业资讯)–设计、开发基于病毒的免疫抗癌药的生物技术公司Transgene (Euronext Paris: TNG)和IT和网络技术领先者NEC Corporation (NEC; TOKYO:...
View ArticleClik here to view.
Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial...
SHANGHAI & ST. HELIER, Jersey Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company...
View Article